2599039-60-6

2599039-60-6 structure

Name: Ogalvibart
Chemical Name: Ogalvibart
CAS Number: 2599039-60-6
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2023-01-28 11:08:05
Modify Date: 2024-02-04 16:27:07
Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1].

Name	Ogalvibart

Description	Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
Target	SARS-CoV-2[1].
In Vivo	Ogalvibart (C-135-LS; 10 mg/kg; 感染前 75 天给药) 联合 10 mg/kg 的 C144LS 时，能有效阻断恒河猴疾病模型中 COVID19 的发展[1]。 Animal Model: Rhesus macaques (3-11 years old)[1]. Dosage: 10 mg/kg (in combination with 10 mg.kg C144LS) Administration: 75 days before infection Result: Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
References	[1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444.

No Any Chemical & Physical Properties